Evozym Biologics Announces Changes to Board of Directors

        Print
| Source: Evozym Biologics, Inc.

LEWES, Del., June 24, 2014 (GLOBE NEWSWIRE) -- Evozym Biologics, Inc. ("Evozym" or the "Company") today announced that Dr. Marc Hertz and Dr. Jay Cullen have joined its Board of Directors.

Dr. Hertz, who was also named Evozym's Chairman, brings to the Company more than 20 years of experience in the field of biotechnology and immunology. Formerly CEO of Pharmexa, Inc. and Managing Director of Birdrock Biotech Consultancy, Dr. Hertz is currently Chairman of Mutimeric Biotherapeutics and CEO of GRI Bio, Inc. He is a graduate of Bowdoin College with a BA in Biology, and holds a doctorate degree in Immunology from the University of Colorado Anschutz Medical Campus.

Dr. Cullen is a professor at the University of Victoria's School of Earth and Ocean Sciences (British Columbia, Canada), where he specializes in biogeochemistry and chemical oceanography. Over the past 20 years, he has been at the forefront of oceanographic research. He holds a Bachelor in Science Degree from McGill University and a doctoral degree from Rutgers University, and was also a postdoctoral scholar at Woods Hole Oceanographic Institution.

In connection with these developments, Evozym's President Dr. Joseph Grzymski stated, "We are extremely honored and privileged to add to our Board individuals with depth of expertise in biology, biochemistry, healthcare and life sciences. I am optimistic that Marc and Jay's experience will prove invaluable as we continue to develop our platform technology for biopharmaceutical drug-targeting and diagnostics."

About Evozym Biologics, Inc.

Evozym Biologics, Inc., is an evolutionary and environmental biology company revolutionizing statistical genomics to exploit new potentials for diagnostics, drug-targeting and bioengineering. Two professors, Joseph J. Grzymski and Adam G. Marsh, with more than 25 years research experience, founded the Company. Evozym's proprietary platform technology utilizes evolutionary biology combined with multi-core computation, proprietary algorithms, databases and biological engineering to address the needs of multiple facets of the drug discovery process. Evozym's technology facilitates the development of novel diagnostics and disease biomarkers, the identification and validation of novel drug targets and the evolution of known gene profiles into novel proteins with enhanced properties that meet specific goals. For more information, please visit www.evozym.com

JOSEPH J. GRZYMSKI, PH.D., PRESIDENT
EVOZYM BIOLOGICS, INC.

775.453.6373